Topics: Slide Management
Topics: Digital Pathology
If the dialogue at ASCO this month was any indication, oncologists, who I tremendously respect, actually know about digital pathology. In many instances their research and/or clinical facilities already use the technology. Oncologists were familiar with whole slide scanning, image analysis and analytics, and the ability to have cases reviewed quickly without the need to transport glass slides – having seen it successfully used for tumor boards and education in their own institutions.
Topics: Digital Pathology
On a recent trip, to present at grand rounds at a well-known midwestern medical school, I noticed a dapper gentleman on my flight. He was wearing a three-piece suit and carrying an impressive attaché case. He stood out among the many travelers dressed in shorts and flip-flops, and who probably wished they hadn’t when we reached our destination where the weather was not as friendly.
Whole slide scanning of pathology slides is becoming more affordable and convenient for building the foundation of a laboratory’s digital pathology service.
Once you’ve obtained a whole slide scanner and your laboratory has developed an effective workflow for scanning images of pathology slides from your cases, you can store your whole slide images (WSI) on a server making them easily accessible from your laptop or tablet. As your image repository grows, however, finding the images you need becomes a challenge.
Most WSI directories are based on laboratory accession numbers. When needing to access images to demonstrate certain features, whether for research, teaching, publication, creating digital study sets or other applications, you must first determine which cases will potentially have the images that best demonstrate what you want to show.
Topics: digital imaging
A Move by the FDA Signals Possible Classification for Patient Safety and Industry Collaboration
On Jan. 14, 2016, the Digital Pathology Association (DPA) issued a press release suggesting “digital pathology manufacturers currently interested in marketing whole slide imaging (WSI) devices for primary diagnosis in the United States submit de novo applications to the Food and Drug Administration (FDA).”
What exactly does this mean?
The press release goes on to say, “The FDA had previously stated it considered WSI for primary diagnosis to be a Class III medical device. However, FDA had never formally
At Pathology Visions 2015 Corista hosted a reception featuring guest speaker, Dr. Arief Suriawinata, Chief of Anatomic Pathology at Dartmouth-Hitchcock Medical Center in Lebanon, NH. Dr. Suriawinata spoke on “The Dartmouth Experience: Whole Slide Imaging, Workflow and Quality Assurance”.
Dr. Suriawinata noted that while whole slide imaging is here to stay, its implementation is not without challenges in terms of integration, workflow, support, data storage and, last but not least, pathologists’ comfort. He emphasized that the key to successful implementation is a well-designed workflow providing whole slide images (WSI) of excellent quality to pathologists and residents where and when they need them.
Dartmouth-Hitchcock’s experience using WSI for its quality assurance program and how the program prepares pathologists for the utilization of telepathology generated a lively discussion on today’s key issues in digital pathology.
Topics: Slide Management
There is a decades-old theorem first derived at the Mayo Clinic that although based on little actual data has been popularized over the years stating:
This is a lot of bang for the buck. Imagine 70% of objective information assisting in 70% of healthcare decisions for as little as 5% of total healthcare expenditures.
This piece discussed the issues surrounding what is perceived by many as the increasing (and necessary) sub-specialization in pathology. The model of "everybody doing everything” has evolved into “everybody doing one thing".
Historically, practicing pathologists were solid general surgical pathologists, often times with their own expertise/interest in a particular area, but they prided themselves on being "surgical pathologists" rather than "liver", "hemato-" or "dermato-" pathologists as in today’s world. A number of factors have driven and resulted in this trend.
First and foremost, the needs of the market. Dedicated specialists in breast or gastrointestinal diseases are commonplace in medicine including the radiologist, surgeon, oncologist and radiation therapist. Pathology appropriately responded accordingly. Secondly, pathologists have driven some our own marketing and needs. The resulting potential problems are paramount and based on many fallacies.
Dr. Keith Kaplan, Chief Medical Officer for Corista, LLC, offers his thoughts on “The State of Pathology Today” and some strategies for facing today’s challenges.
Today, the state of pathology, along with our national leadership and organizations, seems fragmented and without direction. I attended the College of American Pathologists (CAP) and House of Delegates meetings earlier this month, and there seem to be a few issues which we cannot deal with as a group: